Full history for every metric is available with a Kvantra account
MYND Life Sciences Inc. (MYND.CN)
Key financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -2 | -1 | |||||
| Net profit | CAD m | - | -0 | -0 | -4 | -4 | -2 | -1 |
| EPS reported | CAD | -0.03 | -0.01 | |||||
| Operating cashflow per share | CAD | -0.00 | -0.00 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.00 | -0.00 | |||||
| Free cash flow | CAD m | -0 | -0 | |||||
| Net debt | CAD m | 3 | 3 | |||||
| Book value equity | CAD m | -5 | -6 | |||||
| Book value per share | CAD | -0.11 | -0.13 | |||||
| Number of shares | m | 47.27 | 46.27 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.14 | -0.56 | |||||
| P/S LTM | x | 0.00 | 77.35 | |||||
| P/FCF LTM | x | -3.58 | -19.37 | |||||
| EV/EBITDA LTM | x | -2.03 | -4.94 | |||||
| EV/Sales LTM | x | 0.00 | 146.66 | |||||
| Earnings Yield LTM | % | -214.07% | -45.87% | |||||
| FCF Yield | % | -27.96% | -5.16% | |||||
| Quality | ||||||||
| ROE | % | 30.50% | 35.68% | |||||
| ROIC | % | 91.43% | 91.43% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.07 | -0.06 | |||||
| Net Debt/EBITDA | x | -1.64 | -1.64 | |||||
| EBIT/Net interest | x | -2.48 | -2.48 | |||||
| Net debt/market cap | % | 423.07% | 89.61% | |||||
| Net debt/Equity | x | -0.60 | -0.50 | |||||
| Gross debt/equity | x | -0.60 | -0.50 | |||||
Company overview
Headquartered in Kelowna, Canada, MYND Life Sciences Inc. operates as a neuro-pharmaceutical enterprise focused on creating innovative therapies for depressive disorders. The company conducts scientific research and clinical trials across Canada and the United States to develop drugs derived from neuro-anti-inflammatory compounds. A significant part of their work involves the study and development of psilocin and psilocybin extracts, as well as their synthetic analogs.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
MYND Life Sciences Inc. (MYND.CN)
Headquartered in Kelowna, Canada, MYND Life Sciences Inc. operates as a neuro-pharmaceutical enterprise focused on creating innovative therapies for depressive disorders. The company conducts scientific research and clinical trials across Canada and the United States to develop drugs derived from neuro-anti-inflammatory compounds. A significant part of their work involves the study and development of psilocin and psilocybin extracts, as well as their synthetic analogs.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free